{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-027835","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-08-14T12:30:19+00:00","discovered_at":"2026-08-14T12:35:12.426910+00:00","generated_at":"2026-08-14T12:35:25.762694+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Moleculin Q2 2026: MIRACLE CR rates 3x control, cash runway into Q1 2027","bullets":["MIRACLE interim data: CR 43% (190 mg/m²) and 36% (230 mg/m²) vs 12% control; CRc 50% and 57% vs 29%.","Enrollment >80% of 90 patients; data readout Dec 2026-Feb 2027; Part B start 1H 2027.","Cash $7.3M at June 30 plus $9.3M raised post-quarter; runway into Q1 2027.","R&D expenses $5.5M in Q2 2026 vs $3.6M YoY; G&A flat at $2.1M.","No cardiotoxicity observed; ASCO data support cardiac safety profile."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-027835","json":"https://secwatch.observer/filing/0001437749-26-027835.json","markdown":"https://secwatch.observer/filing/0001437749-26-027835.md","text":"https://secwatch.observer/filing/0001437749-26-027835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926027835/0001437749-26-027835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926027835/mbrx20260811_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T12:35:25.762694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}